Lilly

AZ’s Farxiga heart failure results wow the ESC

an entirely new treatment category for these patients – and a whole new revenue stream for AZ as it chases after SGLT2 market leader Jardiance (empagliflozin) from Eli Lilly and Boehringer Ingelheim. ... Those trials are due to read out next year.

Second TULIP trial resurrects AZ’s lupus drug anifrolumab

There are some encouraging signs with other drugs however, including mid-stage clinical results with Incyte/Eli Lilly’s Olumiant (baricitinib), Johnson &Johnson’s IL-12/IL-23 inhibitor Stelara (ustekinumab)

FDA clears Lilly’s Taltz for ankylosing spondylitis

New indication boosts $1bn+ hopes for this year. Eli Lilly’s Taltz can now compete on a level playing field with Novartis’ rival drug Cosentyx, after picking up a third FDA ... mobility, according to Lilly, which says only 15% of patients with the

NICE’s fast-track catapults Skyrizi into market

to be one of a range of suitable treatments, including Cosentyx (secukinumab) and Lilly’s Talz (ixekizumab), then the least expensive should be chosen, once administration costs, dosage, price per dose

Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO

Garraway joins from Eli Lilly. Roche’s chief medical officer and head of global product development, Sandra Horning, will retire later this year after five years in the role. ... Prior to joining Lilly in 2017, Garraway was director of the Joint Centre

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]